---
title: "TriSalus Life Sciences - CW | 8-K: FY2025 Q4 Revenue: USD 13.2 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272266220.md"
datetime: "2026-01-12T12:10:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272266220.md)
  - [en](https://longbridge.com/en/news/272266220.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272266220.md)
generator: "portal-rs"
---

# TriSalus Life Sciences - CW | 8-K: FY2025 Q4 Revenue: USD 13.2 M

Revenue: As of FY2025 Q4, the actual value is USD 13.2 M.

### Financial Metrics by Segment

#### Segment Revenue

-   **Fourth Quarter 2025 Revenue**: Approximately $13.2 million, up 60% year-over-year from $8.3 million in the prior year and a sequential quarterly growth of approximately 14%.
-   **Full-Year 2025 Revenue**: Approximately $45.2 million, up 53% year-over-year from $29.4 million in the prior year.

#### Operational Metrics

-   **Year-End Cash and Cash Equivalents**: Approximately $20.4 million as of December 31, 2025, compared to $22.7 million at the start of the fourth quarter, reflecting a reduction of $2.3 million.

#### Outlook / Guidance

-   **2026 Revenue Guidance**: The company expects full-year 2026 revenues to be in the range of approximately $60 million to $62 million.

### Related Stocks

- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [Oil set for second weekly rise as unsettled US-Iran war crimps supply](https://longbridge.com/en/news/296555193.md)
- [Southern Copper (NYSE:SCCO) Shares Up 8.3%  - Still a Buy?](https://longbridge.com/en/news/296638179.md)
- [Trump Boosted INTC and DELL: Now He Says ‘Do Magnets’—Are MP and USAR Stocks Next?](https://longbridge.com/en/news/296591886.md)
- [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md)
- [MSH Capital Advisors LLC Acquires New Shares in Chevron Corporation $CVX](https://longbridge.com/en/news/296598647.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**